Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.
FDA’s Adverse Event Reporting System (FAERS)
Pembrolizumab
VigiBase
adverse events
data mining
immune checkpoint inhibitors
melanoma
pharmacoepidemiology
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Apr 2020
19 Apr 2020
Historique:
received:
16
03
2020
revised:
14
04
2020
accepted:
15
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
Immune checkpoint inhibition represents an important therapeutic option for advanced melanoma patients. Results from clinical studies have shown that treatment with the
Identifiants
pubmed: 32325840
pii: cancers12041008
doi: 10.3390/cancers12041008
pmc: PMC7226447
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. A.D., A.S., A.-S.K, C.M., D.B.J., F.D., and T.G.S. are employees of Molecular Health GmbH. D.B.J. and T.G.S. have patent applications associated with the analysis of adverse event data.
Références
Diagnostics (Basel). 2018 Oct 31;8(4):
pubmed: 30384507
Oncologist. 2016 Oct;21(10):1230-1240
pubmed: 27401894
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Clin Oncol. 2005 Sep 1;23(25):6043-53
pubmed: 16087944
Clin Cancer Res. 2017 Oct 1;23(19):5666-5670
pubmed: 28235882
Methods. 2015 Mar;74:3-15
pubmed: 25088781
Clin Transl Sci. 2018 May;11(3):322-329
pubmed: 29575568
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
J Immunother Cancer. 2018 May 30;6(1):44
pubmed: 29848375
Nature. 2019 May;569(7756):428-432
pubmed: 31043740
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Neurooncol. 2019 Oct;145(1):1-9
pubmed: 31452071
Biomed Res Int. 2019 Feb 19;2019:6576483
pubmed: 30911546
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Pharmaceuticals (Basel). 2019 Sep 20;12(4):
pubmed: 31546999
Clin Cancer Res. 2017 Jul 15;23(14):3484-3488
pubmed: 28087644
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Clin Med. 2020 Jan 14;9(1):
pubmed: 31947592
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Healthcare (Basel). 2019 Mar 19;7(1):
pubmed: 30893930
Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):483-6
pubmed: 11828828
Trends Immunol. 2015 Apr;36(4):265-76
pubmed: 25797516
Front Pharmacol. 2017 Feb 08;8:49
pubmed: 28228726
Front Immunol. 2018 Jun 28;9:1474
pubmed: 30002656
Medicina (Kaunas). 2019 May 16;55(5):
pubmed: 31100964
Front Pharmacol. 2018 Sep 20;9:1050
pubmed: 30294272
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Clin Drug Investig. 2019 Mar;39(3):319-330
pubmed: 30674039
Melanoma Manag. 2018 Apr 24;5(1):MMT05
pubmed: 30190931
High Throughput. 2018 Nov 23;7(4):
pubmed: 30477159
Semin Oncol. 2010 Oct;37(5):485-98
pubmed: 21074064
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
BioDrugs. 2016 Dec;30(6):571-584
pubmed: 27848165
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):3-10
pubmed: 11998548
JAMA Netw Open. 2019 Sep 4;2(9):e1911519
pubmed: 31532516
Adv Immunol. 2006;90:297-339
pubmed: 16730267
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
Front Med (Lausanne). 2019 May 29;6:119
pubmed: 31192215
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8
pubmed: 17982122